• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

?
-

Resources for You

March 24, 2004 Approval Letter - DECAVAC

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville MD 20852-­1448

March 24, 2004

Submission Tracking Number (STN): BL 103921/5031

Luc Kuykens, MD, DTM, MPH
Aventis Pasteur Inc
Discovery Drive
Swiftwater, PA 18370

Dear Dr. Kuykens:

The Supplement to your Biologics License Application for Tetanus and Diphtheria Toxoids Adsorbed (Td), For Adult Use, to include the addition of a preservative-free, single dose Luer-Lok syringe presentation has been approved.

Under this approval, lots of single dose preservative-free Td Adsorbed shall have an expiration dating period of 24 months when stored at 2-80 C. Any requests to extend the dating period beyond 24 months will require the submission of supporting data as a Supplement to your License Application for review and approval. We have considered your proposed proprietary name DECAVAC in consultation with CBER's Advertising and Promotional Labeling Branch, and we conclude that under 21 CFR Part 201, the proposed proprietary name is acceptable.

We acknowledge the following commitments outlined in your submission dated March 16, 2004.

  1. You have agreed to accumulate real time stability data on final containers for lots --------, ------, and ------- at the following intervals: 6, 9, 12, 18, 24, --------------- months. These stability data will be submitted to CBER for review as they become available. In addition, you have agreed to submit real time stability data on the final formulated bulk vaccine for lots -----, -----, and ----- at intervals of ---------- months as they become available.
  2. You have agreed to accumulate real time stability data on Diphtheria Toxoid, Preservative Free, Adsorbed batches -------------, -------, and ------ at the -- month interval and submit these data to CBER for review.

Please submit four copies of final printed labeling at the time of use with completed implementation information.

This information will be included in your License Application file.

Sincerely yours,

--signature--

Richard I. Walker, Ph.D.
Director
Division of Bacterial, Parasitic and Allergenic Products
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research

 

Contact FDA

(800) 835-4709
(301) 827-1800
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

1401 Rockville Pike

Suite 200N/HFM-47

Rockville, MD 20852-1448